The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.
Katrina H. Smith
No relevant relationships to disclose
Eudocia Quant Lee
Consultant or Advisory Role - Roche/Genentech
Alona Muzikansky
No relevant relationships to disclose
Elizabeth Robins Gerstner
No relevant relationships to disclose
Dan G. Duda
Consultant or Advisory Role - HEXAL / Sandoz
David A. Reardon
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Lakshmi Nayak
No relevant relationships to disclose
Andrew David Norden
No relevant relationships to disclose
Lisa M. Doherty
No relevant relationships to disclose
Jennifer Rifenburg
No relevant relationships to disclose
Debra C. LaFrankie
No relevant relationships to disclose
Sandra Ruland
No relevant relationships to disclose
Julee Pulverenti
No relevant relationships to disclose
Deirdre Stokes
No relevant relationships to disclose
Priscilla Lam
No relevant relationships to disclose
Christine Sceppa McCluskey
No relevant relationships to disclose
Sarah C. Gaffey
No relevant relationships to disclose
Tracy Batchelor
Consultant or Advisory Role - Kirin Pharmaceuticals; Merck; Novartis; Proximagen; Roche
Research Funding - AstraZeneca; Millennium; Pfizer
Rakesh K. Jain
Research Funding - MedImmune; Roche
Patrick Y. Wen
Consultant or Advisory Role - Roche/Genentech
Research Funding - Roche/Genentech; Sanofi/Genzyme